Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,420
-420 (-3.55%)
Jun 27, 2025, 3:30 PM KST

Oncocross Statistics

Total Valuation

Oncocross has a market cap or net worth of KRW 156.16 billion. The enterprise value is 139.58 billion.

Market Cap 156.16B
Enterprise Value 139.58B

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date Aug 12, 2025
Ex-Dividend Date n/a

Share Statistics

Oncocross has 11.95 million shares outstanding. The number of shares has increased by 16.48% in one year.

Current Share Class 11.95M
Shares Outstanding 11.95M
Shares Change (YoY) +16.48%
Shares Change (QoQ) +11.10%
Owned by Insiders (%) 27.31%
Owned by Institutions (%) 11.11%
Float 6.53M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 145.36
PB Ratio 8.52
P/TBV Ratio 8.54
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -19.21
EV / Sales 129.93
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -17.65

Financial Position

The company has a current ratio of 17.18, with a Debt / Equity ratio of 0.02.

Current Ratio 17.18
Quick Ratio 16.90
Debt / Equity 0.02
Debt / EBITDA n/a
Debt / FCF -0.06
Interest Coverage -303.82

Financial Efficiency

Return on equity (ROE) is -43.44% and return on invested capital (ROIC) is -28.49%.

Return on Equity (ROE) -43.44%
Return on Assets (ROA) -27.25%
Return on Invested Capital (ROIC) -28.49%
Return on Capital Employed (ROCE) -41.86%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover 0.06
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 13,098.60
200-Day Moving Average n/a
Relative Strength Index (RSI) 37.00
Average Volume (20 Days) 1,194,137

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Oncocross had revenue of KRW 1.07 billion and -7.26 billion in losses. Loss per share was -670.06.

Revenue 1.07B
Gross Profit 748.05M
Operating Income -7.74B
Pretax Income -7.26B
Net Income -7.26B
EBITDA -7.29B
EBIT -7.74B
Loss Per Share -670.06
Full Income Statement

Balance Sheet

The company has 17.03 billion in cash and 442.10 million in debt, giving a net cash position of 16.58 billion or 1,387.97 per share.

Cash & Cash Equivalents 17.03B
Total Debt 442.10M
Net Cash 16.58B
Net Cash Per Share 1,387.97
Equity (Book Value) 18.33B
Book Value Per Share 1,540.78
Working Capital 16.45B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.79 billion and capital expenditures -1.12 billion, giving a free cash flow of -7.91 billion.

Operating Cash Flow -6.79B
Capital Expenditures -1.12B
Free Cash Flow -7.91B
FCF Per Share -661.92
Full Cash Flow Statement

Margins

Gross Margin 69.63%
Operating Margin -720.41%
Pretax Margin -676.23%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Oncocross does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -16.48%
Shareholder Yield n/a
Earnings Yield -4.65%
FCF Yield -5.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Oncocross has an Altman Z-Score of 55.67 and a Piotroski F-Score of 3.

Altman Z-Score 55.67
Piotroski F-Score 3